Engineering Catalysts for Selective Ester Hydrogenation
作者:Pavel A. Dub、Rami J. Batrice、John C. Gordon、Brian L. Scott、Yury Minko、Jurgen G. Schmidt、Robert F. Williams
DOI:10.1021/acs.oprd.9b00559
日期:2020.3.20
of fluoral hemiacetals under kinetically controlled conditions. Based on experimentalobservations and computational analysis, this paper further extends the current state-of-the-art understanding of the accelerative role of KO-t-C4H9 in ester hydrogenation. It attempts to explain why a maximum turnover is seen to occur starting at ∼25 mol % base, in contrast to only ∼10 mol % with ketones as substrates
当前需要开发有效的催化剂和用于合成官能化的(烯烃和/或手性的)伯醇和氟代半缩醛的方法。这些是制药,农用化学品,香水等的有价值的构建基块。从经济角度看,板凳稳定的高砂国际机场。Corp.的Ru-PNP(通常称为Ru-MACHO)和Gusev的Ru-SNS络合物可以说是最吸引人的从酯和H 2中获取伯醇的分子催化剂(Waser,M.et al.Org.Proc。 RES。开发。2018,22, 862)。这项工作介绍了具有经济竞争力的Ru-SNP(O)z络合物(z= 0,1),它们结合了这两种催化剂的关键结构要素。特别地,发现将SNP杂原子结合到配体骨架中对于在动力学控制条件下合成氟半缩醛中设计更具产物选择性的催化剂至关重要。基于实验观察和计算分析,本文进一步扩展了对KO- t -C 4 H 9在酯加氢中的促进作用的最新认识。它试图解释为什么从大约25 mol%的碱开始出现最大的转化率,而以酮为底物的情况只有10
Direct Access to Cumbersome Aminated Quaternary Centers by Hyperbaric Aza-Michael Additions
addition of secondary amines to α,β- or β,β-disubstituted α,β-unsaturated esters was efficiently achieved under high pressure (10-16 kbar) in protic solvents in the absence of any catalyst. The expected cumbersome β-aminesters bearing a tertiary amine directly connected to a quaternary carbon atom could be isolated in fair to good yields. By using α,β,δ,γ,-unsaturated esters (alkyl sorbate), the addition
[EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERGLYCEMIA AND METABOLIC SYNDROME<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE L'HYPERGLYCÉMIE ET DU SYNDROME MÉTABOLIQUE
申请人:MOHAN M ALAPATI
公开号:WO2016198971A1
公开(公告)日:2016-12-15
The compositions and compounds of formula I, formula II, formula III which includes a molecular conjugate with amino acid L-leucine and a molecular conjugate of polyunsaturated fatty acids or its salts, polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, or injection. Such compositions may be used to treatment of hyperglycemia, metabolic syndrome, diabetes, pre-diabetes, lowering triglycerides or its associated complications.